Loading...
HEMO logo

Hemogenyx Pharmaceuticals PlcLSE:HEMO Stock Report

Market Cap UK£43.2m
Share Price
n/a
1Y245.3%
7D-1.9%
1D-6.6%
Portfolio Value
​
View

Hemogenyx Pharmaceuticals Plc

LSE:HEMO Stock Report

Market Cap: UK£43.2m

Hemogenyx Pharmaceuticals (HEMO) Stock Overview

A clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer in the United Kingdom and the United States. More details

HEMO fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Risk Analysis

Earnings have declined by 18.5% per year over past 5 years

Shareholders have been substantially diluted in the past year

Makes less than USD$1m in revenue (£0)

Volatile share price over the past 3 months compared to the UK market

+ 1 more risk

HEMO Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Top Community Narratives

HEMO logo
Hemogenyx Pharmaceuticals

Significantly undervalued due to several years of reliance on poor UK funding options moving to US based investment.

Active Pipeline: HG-CT-1 - Hemogenyx CAR-T for R/R AML + expanding to pediatrics in H1 2025 targeting FLT3 which has recently been proven as an extremely promising and effective target. Significant interest in CAR-T treatments with each treatment 200k+, licensing deals in the range of 500m->1bn+ (including milestone payments) CDX - Building on same FLT3 target expands use of bi-specific antibody to a whole range of blood borne cancers and diseases including auto-immune.
View narrative
UK£80
FV
92.6% undervalued intrinsic discount
86
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
View all narratives

Hemogenyx Pharmaceuticals Plc Competitors

Price History & Performance

Summary of share price highs, lows and changes for Hemogenyx Pharmaceuticals
Historical stock prices
Current Share PriceUK£5.94
52 Week HighUK£18.00
52 Week LowUK£1.69
Beta1.5
1 Month Change-21.79%
3 Month Change-13.91%
1 Year Change245.35%
3 Year Change-7.19%
5 Year Change-27.21%
Change since IPO-50.50%

Recent News & Updates

Recent updates

Analysis Article • Aug 21

Is Hemogenyx Pharmaceuticals (LON:HEMO) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • May 04

Will Hemogenyx Pharmaceuticals (LON:HEMO) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Jan 06

We Think Hemogenyx Pharmaceuticals (LON:HEMO) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Oct 09

Hemogenyx Pharmaceuticals (LON:HEMO) Has Debt But No Earnings; Should You Worry?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Shareholder Returns

HEMOGB BiotechsGB Market
7D-1.9%2.2%-0.2%
1Y245.3%-10.8%15.6%

Return vs Industry: HEMO exceeded the UK Biotechs industry which returned -10.8% over the past year.

Return vs Market: HEMO exceeded the UK Market which returned 15.6% over the past year.

Price Volatility

Is HEMO's price volatile compared to industry and market?
HEMO volatility
HEMO Average Weekly Movement7.9%
Biotechs Industry Average Movement6.9%
Market Average Movement5.0%
10% most volatile stocks in GB Market10.4%
10% least volatile stocks in GB Market2.6%

Stable Share Price: HEMO's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: HEMO's weekly volatility has decreased from 23% to 8% over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
201316Vladislav Sandlerhemogenyx.com

Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer in the United Kingdom and the United States. The company’s lead product candidate is the HG-CT-1 therapy for the treatment of relapsed or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat viral infections derived and for certain cancer and neurological conditions; and CDX bi-specific antibody which eliminates hematopoietic stem cells/hematopoietic progenitors in a patient using bi-specific antibodies; and therapies for the improvement of bone marrow and blood stem cell transplant procedures.

Hemogenyx Pharmaceuticals Plc Fundamentals Summary

How do Hemogenyx Pharmaceuticals's earnings and revenue compare to its market cap?
HEMO fundamental statistics
Market capUK£43.25m
Earnings (TTM)-UK£9.76m
Revenue (TTM)n/a
0.0x
P/S Ratio
-4.1x
P/E Ratio

Is HEMO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HEMO income statement (TTM)
RevenueUK£0
Cost of RevenueUK£0
Gross ProfitUK£0
Other ExpensesUK£9.76m
Earnings-UK£9.76m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-1.44
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did HEMO perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/21 20:43
End of Day Share Price 2026/08/21 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Hemogenyx Pharmaceuticals Plc is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.